Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist engineered for advanced metabolic research. This 39-amino acid peptide demonstrates superior efficacy in glycemic control, weight management, and cardiometabolic parameter modulation compared to single receptor agonists. Our research-grade Tirzepatide is synthesized with pharmaceutical-grade purity for investigating novel mechanisms in metabolic disease pathophysiology and treatment.